Vasculitis is a term for a group of rare diseases that have in common inflammation of blood vessels and there are many types of vasculitis, and they may vary greatly in symptoms, severity and duration. Vasculitis can range from mild to life-threatening and early detection and treatment of severe vasculitis can prevent permanent damage.
In this issue of Rheumatic Disease Clinics, guest editors Drs. Eli Miloslavsky and Anisha Dua bring their considerable expertise to the topic of Vasculitis. Top experts in the field cover key topics such as vasculitis mimics and other related conditions; vasculitis and pregnancy: disease state and medication management; CNS vasculitis: PACNS and CNS manifestations of systemic vasculitis; ENT manifestations of vasculitis; isolated aortitis workup and management; and more. Contains 14 relevant, practice-oriented topics including peds vasculitis: Kawasaki’s and COVID MIS-C; emerging therapies EGPA; managing immunosuppression in vasculitis patients in the time of COVID; future of vasculitis: DEI in vasculitis clinical trials, pathway targets, precision medicine, PROs, models for damage/relapse, biomarkers; and more. Provides in-depth clinical reviews on vasculitis, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
This issue of Rheumatic Disease Clinics, guest edited by Dr. Candace Feldman, is Part II of a two-part issue covering Health Disparities in Rheumatic Diseases. This issue is one of four selected each year by series Consulting Editor, Dr. Michael Weisman. Topics discussed in this issue include, but are not limited to: Disparities in Lupus Care and Outcomes among U.S. Medicaid Beneficiaries, Understanding Risk Factors for Poor Outcomes in a Multiethnic Longitudinal Cohort, Impact of Psychosocial Factors on RA and Lupus Health Disparities, Racial/ethnic and geographic disparities in knee and hip osteoarthritis, Racial/ethnic Disparities in Osteoarthritis Management, Challenges and Strategies to Achieve Equitable Rheumatologic Care Across the World, Strategies to Reduce Disparities, Understanding and Addressing the Provider Biases and the Lack of Diversity in Lupus Clinical Trials, Community-engaged Research: Lupus Conversations, Leveraging Telemedicine as an Approach to Address Rheumatic Disease Health Disparities, and Understanding the Role and Challenges of Patient Preferences in Disparities in Rheumatic Disease Care.
Guest edited by Drs. Jonathan Kay and Sergio Schwartzman, this issue of Rheumatic Disease Clinics will cover Controversies in Rheumatology. This issue is one of four selected each year by our series Consulting Editor, Dr. Michael Weisman of Cedars-Sinai. Articles explore several questions, including, but not limited to: Is triple therapy or methotrexate plus a biologic the initial treatment of choice for RA patients; Is hypo or hyper-uricemia a risk requiring treatment for cardiac morbidity and mortality; Are there benefits and risks to biosimilars from a patient perspective; Should platelet-rich plasma be used to treat osteoarthritis; Is there a role for stem cell therapy to treat cartilage defects in osteoarthritis; Should any rheumatology patient, today, be treated with bone marrow ablation and stem cell transplantation; Is there effective prevention, prophylaxis, or treatment for CPPD arthritis; Is fibromyalgia a psychiatric disease or a pain syndrome; Should cyclophosphamide still be used to treat ANCA-associated vasculitis; Does methotrexate have a place in the treatment of psoriatic arthritis; Should hydroxychloroquine dosing be limited because of potential ocular toxicity; and Should generalized immunosuppression or targeted organ treatment be the best principle for overall management of SLE.
This issue of Rheumatic Disease Clinics, guest edited by Dr. John Davis, will discuss Cancer and Rheumatic Diseases. This issue is one of four selected each year by series Consulting Editor, Dr. Michael Weisman. Topics discussed in this issue include, but are not limited to: rheumatic drugs and malignancy potential, biologic drugs and cancer, methotrexate and cancer, managing rheumatoid arthritis with cancer, Sjogren’s Syndrome and cancer, lupus and cancer, scleroderma and cancer, cancer and spondylarthritis, and cancer immunotherapy.
In this issue of Rheumatic Disease Clinics, guest editors Drs. Eli Miloslavsky and Anisha Dua bring their considerable expertise to the topic of Vasculitis. Top experts in the field cover key topics such as vasculitis mimics and other related conditions; vasculitis and pregnancy: disease state and medication management; CNS vasculitis: PACNS and CNS manifestations of systemic vasculitis; ENT manifestations of vasculitis; isolated aortitis workup and management; and more. Contains 14 relevant, practice-oriented topics including peds vasculitis: Kawasaki's and COVID MIS-C; emerging therapies EGPA; managing immunosuppression in vasculitis patients in the time of COVID; future of vasculitis: DEI in vasculitis clinical trials, pathway targets, precision medicine, PROs, models for damage/relapse, biomarkers; and more. Provides in-depth clinical reviews on vasculitis, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
Scleroderma, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases. Hardening of the skin is one of the most visible manifestations of the disease. It's estimated that about 300,000 Americans have scleroderma. About one third of those people have the systemic form of scleroderma. Since scleroderma presents with symptoms similar to other autoimmune diseases, diagnosis is difficult. This issue will cover: The Genetic Basis of SSc: Genetics, Epigenetics, Mechanisms of Pathogenesis - linking fibrosis, vasculopathy and immune dysregulation, The Role of Autoantibodies in Diagnosis and Prognosis/survival; Managing Raynaud's phenomenon and ischemic ulcers, managing SSc Lung Disease, Monitoring for and Managing Pulmonary Arterial Hypertension, and many more!
In this issue of Rheumatic Disease Clinics, guest editors Drs. M. Elaine Husni? and George A. Karpouzas bring their considerable expertise to the topic of Cardiovascular Complications of Chronic Rheumatic Diseases. Top experts in the field cover key topics such as primary and secondary atherosclerotic cardiovascular (ASCVD) risk prevention in the rheumatic disease, pro-thrombotic and pro-atherogenic anti-phospholipid antibodies, recommendations for the use of NSAIDs and CVD risk, and more. Contains 9 relevant, practice-oriented topics including atherosclerotic cardiovascular risk stratification in the rheumatic diseases; subclinical atherosclerosis evaluation across various vascular territories; lessons from heart and large vessel biopsies in patients with and without autoimmune rheumatic disease; the role of lipoprotein levels and function in atherosclerosis associated with autoimmune rheumatic diseases; and more. Provides in-depth clinical reviews on cardiovascular complications of chronic rheumatic diseases, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
Guest edited by Drs. Daniel J. Wallace and R. Swamy Venuturupalli, this issue of Rheumatic Disease Clinics will cover several key areas of interest related to Best Practices and Challenges to the Practice of Rheumatology. This issue is one of four selected each year by our series Consulting Editor, Dr. Michael Weisman of Cedars-Sinai. Articles in this issue include, but are not limited to: The Economics of Rheumatology Practice in the United States, Manpower trends in rheumatology, Challenges to practicing rheumatology in an academic center, Challenges in practicing rheumatology in a government setting, Challenges to practicing rheumatology in a small private practice setting, Challenges to working in a large multispecialty organization, Challenges to practicing pediatric rheumatology, Clinical trials in rheumatology, Challenges in having an infusion center, Implementing treatment to target in the clinic, Future directions: implementing new technologies in clinical practice, Possible Challenges in Optimizing Medical Education for Rheumatologists, and the challenges of approaching and managing gout.
